We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia.
In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs.
Our corporate headquarters is located in New Jersey.
For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on Twitter at: @InterceptPharma.
healthcare, biotechnology, life sciences, nonviral liver diseases, rare diseases, innovation